The STOP-HF randomized trial found that patients at high risk of HF can avoid clinical HF after intervention when their BNP levels were more than 50 ng/ml; however, they focused on BNP and their participants were older than 45 years (33). The gene discussed is NPPB; the disease is hydrops fetalis.